中文

泓博医药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-29
ItemAmountY/Y
Revenue¥0.17B+1.7%
Gross profit¥0.05B
Operating income¥0.03B
Net income¥0.02B+98.6%
Gross margin31.9%Net margin 13.8%
Revenue Q/Q-1.0%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.12B68.1%
R&D¥0.01B6.2%
SG&A¥0.03B16.0%
Tax & other¥0.00B1.5%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

荣信文化飞沃科技盛帮股份五洲医疗华康洁净和顺科技瑞泰新材普瑞眼科宏源药业杰创智能威尔高同星科技

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies